AstraZeneca Stock Price, News & Analysis (LON:AZN)

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

AstraZeneca declared a dividend on Thursday, July 25th. Stockholders of record on Thursday, August 8th will be given a dividend of GBX 71.90 per share on Monday, September 9th. This represents a dividend yield of 1.07%. The ex-dividend date of this dividend is Thursday, August 8th. The official announcement can be accessed at this link. View AstraZeneca's Dividend History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for AstraZeneca.

18 analysts have issued 12-month price targets for AstraZeneca's stock. Their forecasts range from GBX 5,180 to £100. On average, they expect AstraZeneca's stock price to reach GBX 7,062.50 in the next twelve months. This suggests a possible upside of 2.1% from the stock's current price. View Analyst Price Targets for AstraZeneca.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

News coverage about AZN stock has trended negative on Sunday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AstraZeneca earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for AstraZeneca.

Some companies that are related to AstraZeneca include GlaxoSmithKline (GSK), Bayer (BAYN), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Mayne Pharma Group (MYX), Opthea (OPT), Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Futura Medical (FUM) and Vita Life Sciences (VLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), Vodafone Group (VOD), Hain Celestial Group (HAIN), National Retail Properties (NNN), NVIDIA (NVDA), BP (BP), Marks and Spencer Group (MKS), Royal Dutch Shell (RDSB), Encana (ECA) and Philip Morris International (PM).

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of AZN stock can currently be purchased for approximately GBX 6,916.

AstraZeneca has a market capitalization of £90.73 billion and generates £23.07 billion in revenue each year. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.